Virtus LifeSci Biotech Clinical Trials ETFVirtus LifeSci Biotech Clinical Trials ETFVirtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Clinical Trials ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪9.78 M‬USD
Fund flows (1Y)
‪2.95 M‬USD
Dividend yield (indicated)
1.34%
Discount/Premium to NAV
−0.4%
Shares outstanding
‪550.00 K‬
Expense ratio
0.79%

About Virtus LifeSci Biotech Clinical Trials ETF


Brand
Virtus
Home page
Inception date
Dec 16, 2014
Structure
Open-Ended Fund
Index tracked
LifeSci Biotechnology Clinical Trials Index
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Virtus Advisers LLC
Distributor
VP Distributors LLC
BBC focuses on biotech companies with lead drugs that are still in various phases of clinical trials and not yet approved marketing. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. It excludes companies with a lead drug candidate that’s still in preclinical testing or research stage, prior to entering into human clinical trials. Also excluded are the following 12 distinct sub-industries: Animal Health, Diversified Healthcare, Investment Management, Healthcare Services, Non-Healthcare, Large Pharmaceuticals, Specialty Pharmaceuticals, Medical Devices, Vaccines, Nutraceuticals, OTC Healthcare, or Tools. As such, investors looking for broad biotech exposure, won't find it in BBC. The Index Committee utilizes various public data sources to select portfolio holdings, including, SEC filings, public documents from the U.S. FDA, company press releases and official corporate websites.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Life sciences tools & services
Strategy
Equal
Geography
U.S.
Weighting scheme
Equal
Selection criteria
Proprietary
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
86%12%0.5%
Top 10 holdings
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Broaden your horizons with more funds linked to BBC via country, focus, and more.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
BBC trades at 18.52 USD today, its price has risen 4.10% in the past 24 hours. Track more dynamics on BBC price chart.
BBC net asset value is 17.86 today — it's fallen 0.46% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
BBC assets under management is ‪9.78 M‬ USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
BBC price has fallen by −0.40% over the last month, and its yearly performance shows a −27.99% decrease. See more dynamics on BBC price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −0.46% over the last month, showed a −8.72% decrease in three-month performance and has decreased by −28.73% in a year.
BBC fund flows account for ‪2.95 M‬ USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
BBC invests in stocks. See more details in our Analysis section.
BBC expense ratio is 0.79%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, BBC isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, BBC technical analysis shows the buy rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating BBC shows the sell signal. See more of BBC technicals for a more comprehensive analysis.
Yes, BBC pays dividends to its holders with the dividend yield of 1.34%.
BBC trades at a premium (0.36%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
BBC shares are issued by Virtus Investment Partners, Inc.
BBC follows the LifeSci Biotechnology Clinical Trials Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Dec 16, 2014.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.